Showing results (41-50 of 160) with videos related to

Sort By:
Pageof 16
Plos One|May 15, 2025
Effects of an interprofessional care concept in nursing homes evaluated in the SaarPHIR project: A cluster-randomized controlled trialLisa Tönnies, Viola Zimmer, Alexandra Piotrowski, et al.
Clinical Pharmacology and Therapeutics|May 9, 2022
Renal Transporter-Mediated Drug-Biomarker Interactions of the Endogenous Substrates Creatinine and N<sup>1</sup> -Methylnicotinamide: A PBPK Modeling ApproachDenise Türk, Fabian Müller, Martin F Fromm, et al.
Clinical Pharmacokinetics|May 20, 2019
A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired PatientsDaniel Moj, Hugo Maas, André Schaeftlein, et al.
Pharmaceutics|July 27, 2022
A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction ModelingLaura Maria Fuhr, Fatima Zahra Marok, Maximilian Mees, et al.
Pharmaceutics|June 27, 2020
Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm NeonatesLukas Kovar, Christina Schräpel, Dominik Selzer, et al.
Pharmaceutics|August 26, 2022
Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and RisperidoneSimeon Rüdesheim, Dominik Selzer, Thomas Mürdter, et al.
Molecular Oncology|May 10, 2016
MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibitionLina S Schneider, Melanie Ulrich, Thorsten Lehr, et al.
Pharmaceutics|May 28, 2022
Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction PredictionsHelena Leonie Hanae Loer, Denise Türk, José David Gómez-Mantilla, et al.
Pharmaceutical Research|December 29, 2016
Modeling the Effect of the Selective S1P<sub>1</sub> Receptor Modulator Ponesimod on Subsets of Blood LymphocytesDominik Lott, Andreas Krause, Christian A Seemayer, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 10, 2018
PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and DigoxinNina Hanke, Sebastian Frechen, Daniel Moj, et al.
Pageof 16